Professional background

Dr Rakesh Popat is a consultant haematologist at UCH and honorary associate professor at UCL with specialist expertise in multiple myeloma.

He graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute, Boston USA as part of this.

He has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials programme and is the cancer lead for the NIHR UCLH Clinical Research Facility.

Dr Popat is on the leadership boards of the UK Myeloma Forum, The UK Myeloma Research Alliance and the European Myeloma Network. In addition he is the haematology lead for the North Thames Clinical Research Network.

Research interests

Experimental treatments for cancer, with a particular interest in immunotherapy and multiple myeloma


Antibody-drug conjugates for multiple myeloma. McMillan A, Warcel D, Popat R. Expert Opin Biol Ther. 2020 Aug 12:1-13. doi: 10.1080/14712598.2020.1802422.
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Ophthalmol Ther. 2020 Jul 25. doi: 10.1007/s40123-020-00280-8.

Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Br J Haematol. 2020 Jun 14. doi: 10.1111/bjh.16889.

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH; United Kingdom Myeloma Forum.Br J Haematol. 2020 Jul;190(2):e83-e86. doi: 10.1111/bjh.16874. Epub 2020 Jun 10.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Gordon LI, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau I, Radford JA, Pérez de Oteyza J, Zinzani PL, Iyer S, Townsend W, Karmali R, Miao H, Proscurshim I, Wang S, Wu Y, Stumpo K, Shou Y, Carpio C, Bosch F. Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23.

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Popat R, Warcel D, O'Nions J, Cowley A, Smith S, Tucker WR, Yong K, Esposti SD.Haematologica. 2020 May;105(5):e261-e263. doi: 10.3324/haematol.2019.235937. Epub 2020 Feb 27.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6.

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD.Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.Br J Haematol. 2019 May;185(3):573-578. doi: 10.1111/bjh.15551. Epub 2018 Aug 20.

A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D'Sa S, Rabin N, Popat R, Yong K.Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9.
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. El-Sharkawi D, Ng CH, Payne EM, Yong KL, Ardeshna KM, Khwaja A, Townsend W, Popat R. Br J Haematol. 2019 Apr;185(2):344-347. doi: 10.1111/bjh.15457. Epub 2018 Jul 5.

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat. Cavenagh JD, Popat R.Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):501-507. doi: 10.1016/j.clml.2018.05.007. Epub 2018 May 24.

Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. Popat R, Dowling E, Achhala S, Pandit D, Rabin N, Kyriakou C, Mackinnon S, Yong K, Wechalekar A.Br J Haematol. 2018 Sep;182(6):936-939. doi: 10.1111/bjh.14897. Epub 2017 Aug 18.

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, D'Sa S, Dikaios N, Sokolska M, Antonelli M, Ourselin S, Yong K, Taylor SA, Halligan S, Punwani S. Eur Radiol. 2017 Dec;27(12):5325-5336. doi: 10.1007/s00330-017-4907-8. Epub 2017 Jun 27.

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network. Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Latifoltojar A, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, Dikaios N, Sokolska M, Rismani A, D'Sa S, Punwani S, Yong K. Br J Haematol. 2017 Jan;176(2):222-233. doi: 10.1111/bjh.14401. Epub 2016 Oct 21.